Osteodifferentiated Mesenchymal Stem Cells from Bone Marrow and Adipose Tissue Express HLA-G and Display Immunomodulatory Properties in HLA-Mismatched Settings: Implications in Bone Repair Therapy

Table 2

MSC from AT after osteodifferentiation and licensing by IFN-γ and TNF-α do not induce PBMC proliferation in allogenic conditions.

R : S^a; ratio	MSC-AT	MSC-AT; IFN-γ/TNF-α	Os-MSC-AT	Os-MSC-AT; IFN-γ/TNF-α
1 : 0.5	5.6±1.0^b	7.2±3.1	1.1±0.2	0.9±0.6
1 : 0.25	5.5±1.5	5.2±2.6	1.3±0.3	0.8±0.5
1 : 0.12	5.3±1.5	4.7±2.9	1.0±0.3	1.1±0.8
1 : 0.06	5.3±2.0	5.5±3.0	1.0±0.2	1.3±1.0
1 : 0.03	4.6±1.1	3.9±2.0	1.4±0.3	1.8±1.3

aPBMC from healthy individuals were used as responder cells towards AT-derived MSCs pretreated with IFN-γ and TNF-α (MSC-AT IFN-γ/TNF-α) or not (MSC-AT) as stimulating cells at various responder : stimulator (R : S) ratios. Similar experiments were performed with AT-derived MSCs committed to osteodifferentiation process and pretreated with IFN-γ and TNF-α (Os-MSC-AT IFN-γ/TNF-α) or not (Os-MSC-AT) as stimulating cells.
^bData are mean ± s.e.m. of alloproliferation percentage obtained with 4 and 3 distinct healthy donors for MSC-AT and Os-MSC-AT experiments, respectively. This percentage is calculated considering PBMC stimulated with LCL* as 100% alloproliferation.